We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Study Links Longer Sleep Duration to Worse Cognitive Performance in Menopausal Women

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Experts frequently tout the value of a good night's sleep. However, a new study casts doubt on the value of sleep time suggesting that women who experience night sweats are more vulnerable to cognitive dysfunction as their sleep duration increases. These paradoxical study results will be presented during The North American Menopause Society (NAMS) Annual Meeting in Chicago, September 25-28, 2019.

Previous studies have demonstrated the association between daytime hot flashes and worse memory performance. In this new study involving women with a history of breast cancer, however, researchers focused on night sweats and how they relate to total sleep time. Surprisingly, more frequent night sweats were associated with greater sleep duration. Even more ironic, however, was the finding that these same women experiencing night sweats became more vulnerable to prefrontal cortex deficits, including decreased attention and executive function, as their sleep duration increased. Total sleep time, however, was unrelated to memory performance.

Separately it was determined that daytime hot flashes had no impact on total sleep time.

"This work presents novel insights into the influence of menopause symptoms on cognitive performance among women with a history of breast cancer and raises the possibility that hot flash treatments could benefit cognition in these women through effects on sleep," says John Bark, lead author of the study from the behavioral neuroscience doctoral program at the University of Illinois at Chicago.

"Studies like this are valuable in helping healthcare providers develop effective treatment options for menopausal women complaining of cognitive decline as they focus on modifiable risk factors," says Dr. Stephanie Faubion, NAMS medical director.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.